Key result
Mycophenolate mofetil treatment significantly reduced interstitial angiotensin II concentration (454 vs 1,310 pg/ml) in rats with salt-sensitive hypertension.
Population
39 rats: salt-sensitive hypertension induced by 5 weeks of a high-salt diet after short-term infusion of…
Comparison
Mycophenolate mofetil (MMF) treatment vs No MMF treatment
Design
Preclinical
Follow-up
5 weeks
Authors
Loading...
Hypothesis-generating for immunomodulation in salt-sensitive hypertension; human trials needed before any clinical consideration.
Absolute Event Rate: 454% vs 1310%
In a rat model of salt-sensitive hypertension, mycophenolate mofetil reduces renal interstitial inflammation and angiotensin II concentrations, which correlate positively with blood pressure.
Franco et al. (2007) studied salt-sensitive hypertension (n=39). Mycophenolate mofetil (MMF) vs. No MMF treatment was evaluated on interstitial angiotensin II (AII) concentration. Mycophenolate mofetil treatment significantly reduced interstitial angiotensin II concentration (454 vs 1,310 pg/ml) in rats with salt-sensitive hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: